have recently been of interest are extracellular vesicles (EVs), which encompass microvesicles, apoptotic bodies, and exosomes. 10, 11 based on their urine EV transcript expression levels. 15 In our current study, we have investigated the RNA content of cell pellets and EVs recovered from urine specimens to assess their suitability for transcriptome-wide analysis and biomarker discovery.
| MATERIALS AND METHODS

| Patient cohort
Cohort participants were patients at primary care and urology clinics of Healthcare's medical records database, and are summarized in Table 1 .
This study was conducted with the approval of the institutional review board of Emory University.
| Urine collection and processing
For patients undergoing prostate biopsy or radical prostatectomy, all specimens (including serum for PSA testing) were collected prior to these procedures. Following an attentive DRE performed by a clinical care provider, each patient provided a first-catch urine sample directly into 30 mL specimen containers. All urine specimens were transported on crushed ice to the laboratory for processing within 4 h of collection.
Urine specimens were centrifuged for 5 min at 700g at 6°C to pellet the cells and the urine supernatant was transferred to a 50 mL conical tube for further processing. The urine cell pellet was transferred to a non-stick microfuge tube, snap frozen, and stored at −80°C. At this point, urine supernatants processed with the Post-Freeze Filtration protocol had 0.5M EDTA added to a final concentration of 40 mM and were stored at −80°C with the filtration processing to be performed at a later date (generally within 2 weeks of collection), while urine supernatants processed using the Same Day Filtration protocol continued through the following procedure on the day of collection (Supplementary Fig. S1A ). Urine supernatants were centrifuged at 2000g for 5 min at room temperature to remove cell debris before being filtered through a 0.8 μm syringe filter. The filtered supernatant specimens were then centrifuged through an Amicon Ultra-15
Centrifugal Filter Unit with Ultracel-100 membrane at 3400g at 21°C for 10 min. The flow-through was discarded and the centrifugation step repeated until the entire sample had been passed through the filter unit. The filter unit was then washed with 15 mL of PBS and centrifugation at 3400g at 21°C for 10 min. Supplementary Fig. S1A ), or they were immediately carried through to the RNA isolation protocol below (samples processed with the Post-Freeze Filtration protocol; Supplementary   Fig. S1A ).
| RNA isolation
Total EV RNA was extracted using the Qiagen RNeasy Micro Kit and total urine cell pellet RNA was extracted using the Qiagen AllPrep DNA/RNA Micro Kit. Each of these methods were carried out according to manufacturer's instructions, and included an on-column DNase I treatment. To elute the RNA, the spin column was transferred to a non-stick microfuge tube containing 1 µL of GlycoBlue solution
(1 µg/µL), and then 20 µL of RNase-free water (pre-warmed to 45°C) was added directly to the spin column membrane. Following incubation at room temperature for 5 min, the spin column was centrifuged for 1 min at 20 000g. The Agilent RNA Pico Kit and
Bioanalyzer were used to determine RNA concentration and quality.
| Transmission electron microscopy (TEM)
A 5 µL aliquot of each urine EV sample was deposited onto a 400 mesh carbon coated copper grid that had been glow-discharged for 20 s.
Grids containing EV samples were placed in a covered glass dish to allow vesicles to settle. After 5 min, each grid was washed by briefly touching the sample side to three drops of de-ionized water. Excess water was then removed from the grid with filter paper, and the sample was stained with 1% phosphotungstic acid (pH 6.5) for 20 s.
Phosphotungstic acid was removed with filter paper and the samples were left to air dry for 10 min. Imaging was done on a JEOL JEM-1400 transmission electron microscope equipped with a 2k × 2k Gatan US1000 CCD camera.
| Gene expression analysis by TaqMan qPCR
The transcripts of interest were analyzed using TaqMan Gene
Expression Assays (details included in Supplementary Table S1 ). Up 
RAB7A.
Cycle threshold values for non-detected assays were set to 40.
| Measurement of gene expression by precise assay
Gene expression was also assessed using the multiplex Precise Assay technology developed by Cellular Research. In this method, each RNA transcript is labeled with a unique molecular index during reverse transcription allowing measurement of the number of transcripts in the original starting material. 16, 17 Each reaction was performed using 1 ng of RNA with each specimen run in triplicate.
Amplification was conducted for a targeted set of genes according to Bridges Genomics platform and molecular index counts were used to perform expression analysis. Molecular index counts were retained if the average over the three technical replicates was at least five, and the data were normalized to the reference gene, RAB7A. When fewer than five molecular index counts were detected, the relative expression was set to 0. higher for the EV specimens, as the majority of EV specimens (89 specimens, 84.8%), but fewer than half of the cell pellet specimens (46 specimens, 43.8%) had a RIN ≥ 5 (Fig. 1C ). The samples with low RINs included 17 cell pellets and 3 EV specimens that were too low in concentration or quality for a RIN to be determined ( 3.3 | Extracellular vesicle RNA yields are significantly lower in urine collected without DRE
| Statistical analysis
We also determined that the application of a DRE immediately prior to urine collection was necessary for the recovery of sufficient EV RNA. Urine collections from 36 consecutive patients were randomly performed either with or without a prior DRE. The median EV RNA yield from post-DRE urine was 36.9 ng (IQR:
11.6-79.3 ng), which was similar to that observed in the larger cohort described above ( Supplementary Fig. S3 ). However, urine collected without a DRE had a significantly lower median EV RNA yield of 3.1 ng (IQR: 1.7-4.0 ng; Wilcoxon rank sum test P < 0.001; Supplementary Fig. S3 ). As urine may contain molecules originating from tissues throughout the genitourinary system, we used TaqMan qPCR to assess genes considered to have prostate-, kidney-, or bladder-specific expression to better understand the relative contribution of each of these tissues.
These genes were selected based on a previous study that performed whole transcriptome RNA sequencing on EVs from urine collected without a prior DRE to investigate a range of transcripts representing different regions of the kidney and bladder. 18 Overall, the prostatespecific transcripts had much higher expression levels than any of the kidney-or bladder-specific transcripts we assessed. The highest In contrast, the highest expressed of the kidney-and bladder-specific transcripts, UPK2, had a median normalized expression of 0.002 (IQR:
0.001-0.004; Fig. 3 ). This is over 2-fold lower than the level observed for TRPM8, and almost 30 times lower than HOXB13. The values for all other kidney-and bladder-specific transcripts we assessed were less than 0.001, with a number of them not detectable in all 60 samples (AQP2, CUBN, NPHS2, and SLC34A1 were detected in 52, 59, 40, and 58 specimens, respectively). Patients with GS6 prostate cancer showed a 6.4-fold increase over patients with no evidence of disease, although this was not significant (Welch's two-sample t-test P = 0.116). There was also no significant difference between the GS6 and GS7+ patient groups (1.6-fold, Welch's two-sample t-test P = 0.433; Fig. 4C ).
3.6 | Prostate-specific transcripts are also detectable via multiplex precise assay
After performing the individual assays, we were interested in investigating a novel method for multiplex transcript analysis that could expand our ability to discover and detect urinary RNAs. The
Precise Assay technology encodes each RNA transcript with a unique molecular index during reverse transcription before any amplification has occurred. Analysis of these molecular index sequences is intended to distinguish the number of molecules in the starting material from PCR duplicates arising during amplification. 16, 17 A comparison of the raw data generated by the individual TaqMan qPCR assays and the multiplex Precise Assay is provided in Supplementary Fig. S4 .
In agreement with the TaqMan qPCR analysis, the multiplex
Precise Assay demonstrated that the prostate-specific transcripts, KLK3, KLK2, HOXB13, and TRPM8, were more abundantly expressed than the kidney-or bladder-specific transcripts (Fig. 5A) . However, the highest expressed transcript detected in the Precise Assay was KLK3, at approximately 10-fold higher abundance than the next highest expressed transcript, KLK2. In contrast, KLK3 and KLK2 had very similar expression levels when assessed by TaqMan qPCR, where the highest expressed transcript was HOXB13 (Fig. 3) . Analysis of the readto-molecule ratio of the prostate-associated genes and RAB7A
indicated that most of the transcripts were amplified at similar levels, with approximately 10 sequence reads for each molecule. However, HOXB13 showed a relatively low ratio (3.8 reads/molecule) suggesting that amplification of this transcript in the Precise Assay was less efficient than the other transcripts (Fig. 5D) . The Precise Assay also demonstrated very low expression of the kidney-and bladder-specific transcripts, with none being detected in all 60 samples. In particular, NPHS2, PTH1R, and SLC34A1 were not detected in any sample and are shown with a normalized expression of zero (Fig. 5A ).
When we focused our analysis on the prostate cancer-associated genes, the largest difference between the TaqMan and Precise approaches was that ERG could not be detected by Precise Assay.
However, the Precise Assay demonstrated similar patterns of expression to TaqMan qPCRs when assessing differences in KLK3
and PCA3 amongst each of the patient groups. While KLK3 was very highly expressed, there was no significant difference between patients with GS6 or GS7+ prostate cancer when compared to patients with no evidence of disease (ANOVA P = 0.864; Fig. 5B ). The rate of detection for PCA3 was lower by Precise Assay, where it was only detected in 50% of the patients with no evidence of disease (6 out of 12), 71% of the patients with GS6 prostate cancer (10 out of 14) , and 77% of patients with GS7+ prostate cancer (20 out of 26). Mean expression of PCA3 was 2.5-fold and 3.3-fold higher for patients with GS6 and GS7+
prostate cancer, respectively, as compared to patients with no evidence of disease, although only the increase in the GS7+ group was statistically significant (Welch's two-sample t-test P = 0.052 and P = 0.003; Fig. 5C ). As observed with the TaqMan qPCR assay, there was no significant difference in PCA3 expression between patients FIGURE 3 Prostate-specific genes are enriched in post-DRE urine EVs. The expression of various prostate-, kidney-, or bladder-specific transcripts were measured by TaqMan qPCR and are shown relative to the expression of RAB7A (n = 60). The boxplots for AQP2, CUBN, NPHS2, and SLC34A1 include data for samples where no amplification was observed and the cycle threshold was set to 40 (8, 1, 20 , and 2 samples, respectively) FIGURE 4 Prostate cancer-associated RNAs are detectable and informative in post-DRE urine EVs. The expression levels of (A) KLK3, (B) PCA3, and (C) ERG were measured by TaqMan qPCR assay and normalized to RAB7A. The data are shown for patients with no evidence of disease (N.E.D., n = 12), Gleason score 6 prostate cancer (GS6, n = 14), or Gleason score ≥7 prostate cancer (GS7+, n = 26). The ERG plot includes data for nine samples where no amplification was observed and the cycle threshold was set to 40 (2, 2, and 5 samples for the N.E.D., GS6, and GS7+ groups, respectively). In comparison to the N.E.D. group, the GS6 and GS7+ groups both had significantly higher expression of PCA3 (P = 0.002 and P < 0.001, respectively), while only the GS7+ group both had significantly higher expression of ERG (P = 0.027). There was no significant difference in KLK3 expression between the any of the groups (P = 0.672) PELLEGRINI ET AL.
| 995 with GS6 and GS7+ prostate cancer (1.4-fold, Welch's two-sample t-test P = 0.327; Fig. 5C ).
| DISCUSSION
While urine assays for PCA3 and TMPRSS2:ERG have provided more options and improved detection for men at risk of prostate cancer, the discovery of additional urinary biomarkers is needed to improve the sensitivity and specificity of this approach before it could have a meaningful role in pre-biopsy decision-making. This study was focused on understanding how to recover RNAs from post-DRE urine for comprehensive discovery studies. Our initial findings established that urine EVs had significantly higher quantities of intact RNA than urine cell pellets, regardless of the cancer-status of the patients. In particular, usable amounts of RNA were most reliably recovered from the EV fraction of post-DRE urine, indicating that urine EVs are more suitable for further expression analyses. Additionally, during our optimization of the urine EV isolation protocol, we found the yield of EV RNA to be unaffected following frozen storage of urine supernatants, suggesting that urine EVs are stable at low storage temperatures and during freeze-thaw. This is further supported by previous observations that exosomes and microvesicles remain intact throughout repeated freeze-thaw cycles. [19] [20] [21] This demonstrates the potential for implementation of urine EV-based assays at clinics lacking on-site laboratory facilities, and the possibility of isolating urine
EVs from archived urine supernatants. completely absent. 24, 25 In one of these studies, rRNAs that were originally assumed to be eukaryotic were actually found to be 16S and FIGURE 5 Precise Assay measurement of transcripts also shows enrichment of prostate-specific and prostate cancer-associated transcripts.
(A) The same prostate-, kidney-, and bladder-specific transcripts shown in Fig. 3 were assessed by Precise Assay and normalized to RAB7A (n = 60). KLK3 is shown on a different scale because it was present at much higher levels than the other transcripts. The boxplots for AQP2, CUBN, NPHS2, PTH1R, SLC12A1, SLC12A3, SLC34A1, UPK1B, and UPK2 include data for samples where no transcripts were detected and the normalized expression was set to 0 (17, 7, 60, 60, 15, 54, 60, 17 , and 22 samples, respectively). Transcripts for (B) KLK3 and (C) PCA3 were measured by Precise Assay and normalized to RAB7A (n = 12, 14, and 26 for the N.E.D., GS6, and GS7+ groups, respectively). The PCA3 plot includes data for 14 samples where no transcripts were detected and normalized expression was set to 0 (6, 4, and 6 samples for the N.E.D., GS6, and GS7+ groups, respectively). GS7+ patients had significantly higher expression of PCA3 as compared to the N.E.D. group (P = 0.003).
(D) The ratio of sequence reads to molecular index count is shown for all of the prostate-associated genes and the normalizer RAB7A (means and 95% confidence intervals shown)
23S prokaryotic rRNA peaks from contaminating bacteria in the urine. 25 We have confirmed that the rRNAs in our post-DRE urine EV specimens are eukaryotic, indicating that mixed urine EV populations can contain the full complement of RNAs and that contaminating prokaryotic species are unlikely to have contributed significantly to our observed RNA yields. However, it would not be appropriate to use our results to demonstrate the relative presence of small RNAs to larger RNA species as the RNA extraction method we have used is not intended for the recovery of small RNAs (<200 nucleotides).
One of the complications of urine-based biomarkers is the possibility for genes expressed by other tissues in the genitourinary tract to contribute to the detected signal. However, we found prostatespecific genes to be present at much higher levels than any of the kidneyor bladder-specific genes indicating that urinary EVs are enriched for demonstrated that these genes are expressed at higher levels in the urine vesicles of patients with prostate cancer and substantiates the rationale for using post-DRE urine EV RNA as a biomarker source. 15, 27 KLK3 was very highly expressed in urine EVs from all patients, but showed no significant difference between the three patient groups. Given that KLK3
is not specific for cancer and is currently used as a normalizer gene for the PCA3 and TMPRSS2:ERG urine assays, 3 this consistent expression across all of the patient groups fits with its expected performance and supports the validity of studying urine EVs.
Our experience with the Precise Assay indicated that there was some loss of detection sensitivity when using the multiplex platform, as opposed to the robust detection in all or most of the specimens when using individual TaqMan qPCR assays. In particular, none of the kidney and bladder transcripts could be detected in all 60 specimens when using the Precise Assay, and a number of the transcripts (NPHS2, PTH1R, and SLC34A1) were not detected in any sample with this method. The number of specimens with detectable PCA3 and ERG was also reduced when using the Precise Assay. There are a number of possible reasons for the differences in sensitivity of the two methods, although a large contributing factor may be the low RNA input (1 ng) used in the Precise Assay. While being able to use less RNA is appealing due to ensuring that more specimens are able to meet the required input, it does introduce complications when trying to detect transcripts of lower abundance, with lack of detection and high variability between replicates becoming more likely. Another factor that may have influenced the comparative performance of the two assays are the relative efficiencies of the reverse transcription and amplification for each method. This may be best demonstrated by the difference in the apparent abundance of HOXB13, which was less efficiently amplified by the Precise Assay than the other prostatespecific transcripts. Future iterations of this assay will need to be carefully designed to ensure that all concurrently amplified transcripts can be adequately and accurately detected.
Although this study was limited to known urine biomarkers while we focused on characterizing the RNA and investigating the implementation of this technique, the Precise Assay technology that we have used is capable of detecting up to 150 genes simultaneously. Prognostic biomarker panels assessed in biopsy or radical prostatectomy tissue generally assess 20-30 genes to create an overall risk score [28] [29] [30] [31] and the combination of the PCA3 and TMPRSS2:ERG urine assays demonstrates that the performance of urine biomarker panels can also be improved with the addition of more genes. [5] [6] [7] This proof of principle study has better characterized the RNA recovered from post-DRE urine EVs, and demonstrated the feasibility of performing multiplex gene expression analyses in this specimen type. We are currently expanding our analysis to include additional prostate cancer-associated genes that have not previously been investigated in urine. The ability to recover sufficient urinary RNA to conduct comprehensive gene expression analysis is likely to accelerate the development of urine biomarker panels for the accurate determination of prostate cancer risk prior to biopsy.
| CONCLUSIONS
We have demonstrated that post-DRE urine EVs are a more reliable source of RNA than urine cell pellets, that prostate-specific transcripts are enriched in these EVs, and that the current urinary prostate cancer biomarkers, PCA3 and ERG, are present at significantly higher levels in the urine EVs of prostate cancer patients. These findings indicate that prostate cancer status is reflected in urinary EVs, and that continued analysis of urine EVs offers the potential to discover additional biomarkers for prostate cancer detection.
